Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Short Interest Up 215.3% in July

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) was the target of a large increase in short interest in July. As of July 15th, there was short interest totalling 59,900 shares, an increase of 215.3% from the June 30th total of 19,000 shares. Based on an average trading volume of 1,380,000 shares, the days-to-cover ratio is currently 0.0 days. Currently, 10.7% of the company’s shares are short sold.

Salarius Pharmaceuticals Stock Performance

Shares of NASDAQ:SLRX traded up $1.36 during mid-day trading on Thursday, hitting $3.50. The stock had a trading volume of 31,266,346 shares, compared to its average volume of 858,647. The company has a market cap of $2.10 million, a PE ratio of -0.15 and a beta of 0.92. Salarius Pharmaceuticals has a 12-month low of $1.35 and a 12-month high of $7.92. The company’s 50 day moving average is $2.94 and its 200-day moving average is $3.92.

Salarius Pharmaceuticals (NASDAQ:SLRX) last issued its quarterly earnings results on Monday, May 13th. The company reported ($3.28) EPS for the quarter, beating the consensus estimate of ($53.60) by $50.32. On average, equities research analysts predict that Salarius Pharmaceuticals will post -214.4 EPS for the current fiscal year.

Salarius Pharmaceuticals Company Profile

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.